TEVA

Teva improved margins significantly. The pharmaceutical company has paid down net debt.

Teva's Q3 earnings beat estimates as strong branded drug sales fueled growth, prompting higher 2026 revenue and product sales guidance.

Teva Pharmaceutical Industries NYSE: TEVA reported third-quarter 2026 revenue of approximately $4.4 billion, down 2% from a year earlier, as growth in its innovative medicines portfolio was offset by lower generic-drug sales, particularly generic REVLIMID.

Teva Pharmaceutical Industries Limited ( TEVA ) Q3 2026 Earnings Call November 3, 2026 8:00 AM EST Company Participants Christopher Stevo - Senior Vice President of Investor Relations & Competitive Intelligence Richard Francis - President, CEO & Director Eric Hughes - Executive VP of Global R&D and Chief Medical Officer Eliyahu Kalif - Executive VP & CFO Conference Call Participants Umer Raffat - Evercore ISI Institutional Equities, Research Division Douglas Tsao - H.C. Wainwright & Co, LLC, Research Division Glen Santangelo - Barclays Bank PLC, Research Division David Amsellem - Piper Sandler & Co., Research Division Jason Gerberry - BofA Securities, Research Division Louise Chen - Scotiabank Global Banking and Markets, Research Division Dennis Ding Daniel Christopher Clark - Leerink Partners LLC, Research Division Joseph Thome - TD Cowen, Research Division Christopher Schott - JPMorgan Chase & Co, Research Division Presentation Operator Hello, everybody, and welcome to the Q3 2026 Teva Pharmaceutical Industries Earnings Conference Call.

Although the revenue and EPS for Teva Pharmaceutical Industries (TEVA) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Israeli drugmaker Teva Pharmaceutical Industries, reported on Tuesday ​a higher-than-expected rise in third-quarter ‌profit, helped by strong sales of a trio of its own ​drugs to offset declines in ​copycat medicines.

Teva to obtain U.S. commercialization rights for two immunology biosimilars: ETICOVO® upon close and infliximab-abda in Q3 2027 Collaboration combines Samsung Bioepis' biosimilar expertise with Teva's commercial capabilities Agreement expands collaboration with Samsung Bioepis, strengthening Teva's generics powerhouse and biosimilars portfolio as part of its Pivot to Growth strategy TEL AVIV, Israel and INCHEON, South Korea, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and Samsung Bioepis Co., Ltd.

Teva to discontinue mid-stage neurodegenerative disorder study

Teva's pivot from generic drugs to branded drugs has fueled an 100% surge for shares over the past year. Based on recent results and catalysts, don't rule out a continued, steady move towards higher price levels.

Get a deeper insight into the potential performance of Teva Pharmaceutical Industries (TEVA) for the quarter ended September 2026 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.